Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C9H19N |
| Molecular Weight | 141.2539 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(C)CCC=C(C)C
InChI
InChIKey=XVQUOJBERHHONY-UHFFFAOYSA-N
InChI=1S/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3
| Molecular Formula | C9H19N |
| Molecular Weight | 141.2539 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02290379 | https://www.ncbi.nlm.nih.gov/pubmed/22288671 | https://clinicaltrials.gov/ct2/show/NCT02706015 | https://www.drugbank.ca/drugs/DB06706
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02290379 | https://www.ncbi.nlm.nih.gov/pubmed/22288671 | https://clinicaltrials.gov/ct2/show/NCT02706015 | https://www.drugbank.ca/drugs/DB06706
Isometheptene (usually as isometheptene mucate) is a sympathomimetic amine sometimes used in the treatment of migraines and tension headaches due to its vasoconstricting properties. Isometheptene's vasoconstricting properties arise through activation of the sympathetic nervous system via epinephrine and norepinephrine. These compounds elicit smooth muscle activation leading to vasoconstriction by interacting with cell surface adrenergic receptors.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11485035 |
|||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11485035 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Neosaldina Approved UseUnknown |
|||
| Primary | Neosaldina Approved UseUnknown |
|||
| Primary | Neosaldina Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
120 mg 1 times / episode multiple, oral Studied dose Dose: 120 mg, 1 times / episode Route: oral Route: multiple Dose: 120 mg, 1 times / episode Sources: |
unhealthy, 18 to 65 years Health Status: unhealthy Age Group: 18 to 65 years Sex: M+F Sources: |
Other AEs: Angioneurotic edema, Epigastralgia... Other AEs: Angioneurotic edema (grade 1, 1.3%) Sources: Epigastralgia (grade 1, 1.3%) |
780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
Other AEs: Dizziness, Numbness... Other AEs: Dizziness (17.1%) Sources: Numbness (5.7%) Shortness of breath (2.8%) Chills (2.8%) Nausea (2.8%) Drowsiness (2.8%) |
65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
Other AEs: Abdominal pain, Nausea... Other AEs: Abdominal pain (3.1%) Sources: Nausea (3.1%) Lightheadedness (6.1%) Sleepiness (3.1%) Dry mouth (1.5%) Hot flashes (1.5%) Palpitations (1.5%) Enlarged thyroid (1.5%) Confusion (1.5%) |
325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
Other AEs: Nausea, Vertigo... Other AEs: Nausea (40%) Sources: Vertigo (8%) Lump feeling in throat (8%) Drowsiness (4%) Tachycardia (4%) Itching (4%) Dry mouth (4%) Weakness of limbs (4%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Angioneurotic edema | grade 1, 1.3% | 120 mg 1 times / episode multiple, oral Studied dose Dose: 120 mg, 1 times / episode Route: oral Route: multiple Dose: 120 mg, 1 times / episode Sources: |
unhealthy, 18 to 65 years Health Status: unhealthy Age Group: 18 to 65 years Sex: M+F Sources: |
| Epigastralgia | grade 1, 1.3% | 120 mg 1 times / episode multiple, oral Studied dose Dose: 120 mg, 1 times / episode Route: oral Route: multiple Dose: 120 mg, 1 times / episode Sources: |
unhealthy, 18 to 65 years Health Status: unhealthy Age Group: 18 to 65 years Sex: M+F Sources: |
| Dizziness | 17.1% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
| Chills | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
| Drowsiness | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
| Nausea | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
| Shortness of breath | 2.8% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
| Numbness | 5.7% | 780 mg 1 times / episode multiple, oral Studied dose Dose: 780 mg, 1 times / episode Route: oral Route: multiple Dose: 780 mg, 1 times / episode Sources: |
unhealthy, mean age 33 years Health Status: unhealthy Age Group: mean age 33 years Sex: M+F Sources: |
| Confusion | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Dry mouth | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Enlarged thyroid | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Hot flashes | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Palpitations | 1.5% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Abdominal pain | 3.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Nausea | 3.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Sleepiness | 3.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Lightheadedness | 6.1% | 65 mg 1 times / hour multiple, oral Recommended Dose: 65 mg, 1 times / hour Route: oral Route: multiple Dose: 65 mg, 1 times / hour Sources: |
unhealthy, mean age 40.9 years Health Status: unhealthy Age Group: mean age 40.9 years Sex: M+F Sources: |
| Drowsiness | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Dry mouth | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Itching | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Tachycardia | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Weakness of limbs | 4% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Nausea | 40% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Lump feeling in throat | 8% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
| Vertigo | 8% | 325 mg 1 times / episode multiple, oral Recommended Dose: 325 mg, 1 times / episode Route: oral Route: multiple Dose: 325 mg, 1 times / episode Sources: |
unhealthy, mean age 49 years Health Status: unhealthy Age Group: mean age 49 years Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Epidemiological analysis of doping offences in the professional tennis circuit. | 2010-12-15 |
|
| Managing traumatic brain injury secondary to explosions. | 2010-04 |
|
| Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of life. | 2009-11-03 |
|
| Life threatening intracerebral hemorrhage with isometheptene mucate, dichlorophenazine and acetaminophen combination therapy. | 2009-11 |
|
| Current and prospective pharmacological targets in relation to antimigraine action. | 2008-10 |
|
| Acute migraine: Current treatment and emerging therapies. | 2007-06 |
|
| Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. | 2006-12 |
|
| Intracerebral hemorrhage in postpartum cerebral angiopathy associated with the use of isometheptene. | 2006-11 |
|
| Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study. | 2006-06 |
|
| Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control. | 2005-12-05 |
|
| Fixed drug combinations for the acute treatment of migraine : place in therapy. | 2005 |
|
| Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats. | 2004-05-14 |
|
| Medication use by persons with chronic fatigue syndrome: results of a randomized telephone survey in Wichita, Kansas. | 2003-12-02 |
|
| Migraine: diagnosis, management, and new treatment options. | 2002-02 |
|
| Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs. | 2001-07 |
|
| Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. | 2001-04 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:55:51 GMT 2025
by
admin
on
Mon Mar 31 17:55:51 GMT 2025
|
| Record UNII |
Y7L24THH6T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
520
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
||
|
WHO-ATC |
A03AX10
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
||
|
NCI_THESAURUS |
C29747
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
||
|
WHO-VATC |
QA03AX10
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
576
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
27946
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
22297
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
C75929
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
207-959-6
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
65783-53-1
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
SUPERSEDED | |||
|
DB06706
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
m6501
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB08324MIG
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697841
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
100000082812
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
C008192
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
DTXSID9023172
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
503-01-5
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
Y7L24THH6T
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
1496
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY | |||
|
Isometheptene
Created by
admin on Mon Mar 31 17:55:51 GMT 2025 , Edited by admin on Mon Mar 31 17:55:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |